Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (231-240 of 662) with videos related to

Pageof 67
Sort By:
Stem Cells Translational Medicine|July 14, 2020
Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issuesPeter Valent, Karin Bauer, Irina Sadovnik, et al.
Leukemia & Lymphoma|December 27, 2019
New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019Michel Arock, Karl Sotlar, Jason Gotlib, et al.
European Journal of Clinical Investigation|November 6, 2014
DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemiaPeter Valent, Irina Sadovnik, Zdeněk Ráčil, et al.
Wiener Klinische Wochenschrift|November 20, 2013
Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experienceAlexandra Boehm, Wolfgang R Sperr, Peter Kalhs, et al.
American Journal of Hematology|September 20, 2016
Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapyWolfgang R Sperr, Otto Zach, Iris Pöll, et al.
Journal of Hematology & Oncology|April 18, 2015
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Axel Schulenburg, Katharina Blatt, Sabine Cerny-Reiterer, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 16, 2002
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patientsAbdolreza Rezaie-Majd, Thomas Maca, Robert A Bucek, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 20, 2015
Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergyBirgit Linhart, Margarete Focke-Tejkl, Milena Weber, et al.
International Journal of Molecular Sciences|September 1, 2019
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CMLPeter Valent, Irina Sadovnik, Gregor Eisenwort, et al.
Haematologica|March 7, 2014
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapySiham Bibi, Melis Dilara Arslanhan, Florent Langenfeld, et al.
Pageof 67

Showing results (231-240 of 662) with videos related to

Sort By:
Pageof 67
Stem Cells Translational Medicine|July 14, 2020
Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issuesPeter Valent, Karin Bauer, Irina Sadovnik, et al.
Leukemia & Lymphoma|December 27, 2019
New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019Michel Arock, Karl Sotlar, Jason Gotlib, et al.
European Journal of Clinical Investigation|November 6, 2014
DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemiaPeter Valent, Irina Sadovnik, Zdeněk Ráčil, et al.
Wiener Klinische Wochenschrift|November 20, 2013
Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experienceAlexandra Boehm, Wolfgang R Sperr, Peter Kalhs, et al.
American Journal of Hematology|September 20, 2016
Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapyWolfgang R Sperr, Otto Zach, Iris Pöll, et al.
Journal of Hematology & Oncology|April 18, 2015
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Axel Schulenburg, Katharina Blatt, Sabine Cerny-Reiterer, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 16, 2002
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patientsAbdolreza Rezaie-Majd, Thomas Maca, Robert A Bucek, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 20, 2015
Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergyBirgit Linhart, Margarete Focke-Tejkl, Milena Weber, et al.
International Journal of Molecular Sciences|September 1, 2019
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CMLPeter Valent, Irina Sadovnik, Gregor Eisenwort, et al.
Haematologica|March 7, 2014
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapySiham Bibi, Melis Dilara Arslanhan, Florent Langenfeld, et al.
Pageof 67